PT  - JOURNAL ARTICLE
AU  - ELISABETH CHÉREAU
AU  - CORINNE BEZU
AU  - JOSEPH GLIGOROV
AU  - RITA SAKR
AU  - MARTINE ANTOINE
AU  - EMILE DARAÏ
AU  - SERGE UZAN
AU  - ROMAN ROUZIER
TI  - Impact of Immunohistochemical Analysis of Sentinel Lymph Node Biopsy on Breast Cancer Management
DP  - 2012 Aug 01
TA  - Anticancer Research
PG  - 3403--3409
VI  - 32
IP  - 8
4099  - http://ar.iiarjournals.org/content/32/8/3403.short
4100  - http://ar.iiarjournals.org/content/32/8/3403.full
SO  - Anticancer Res2012 Aug 01; 32
AB  - Background: Little evidence of the impact of immunohistochemical analysis (IHC) on the indications for adjuvant therapies is available. This study determined the modification rate of adjuvant chemotherapy and lymph node area radiotherapy using IHC and its impact on survival. Patients and Methods: Between 2001 and 2005, 416 patients underwent surgery for invasive breast cancer with sentinel lymph node (SLN) biopsy. Results: A total of 112 patients had positive SLNs: 12.5% isolated tumor cells, 35.7% micrometastasis and 51.8% macrometastasis. Only 4% of patients (14 out of 342 patients) had modified indications for chemotherapy and 7% of patients (25 out of 342) for lymph node area radiotherapy due to IHC findings. Conclusion: IHC analysis led to modifications in adjuvant chemotherapy and lymph node area radiotherapy in 4% and 7% of patients, respectively. The prognosis of patients with nodal metastasis discovered by ultrastaging was similar to that for conventional Haematoxylin-Eosin-Safran (HES) staining. Our data support the use of SLN ultrastaging.